CVRx, Inc.

CVRx is a commercial-stage medical device company that develops, manufactures, and sells innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Its primary product, Barostim, is the first medical technology approved by the U.S. Food and Drug Administration (FDA) that uses neuromodulation to improve symptoms in heart failure (HF) patients. Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery wall. This counteracts decreased baroreceptor signaling, which otherwise creates an imbalance in the brain's Autonomic Nervous System (ANS) and leads to excess neurohormones that worsen HF. Barostim provides Baroreflex Activation Therapy (BAT, or Barostim Therapy), which connects the cardiovascular system to the ANS. This therapy works alongside pharmaceutical neurohormonal blockade, or Guideline Directed Medical Therapy (GDMT), by increasing baroreceptor signaling to reduce HF symptoms. Barostim received FDA Breakthrough Device designation and is FDA-approved for HF patients in the U.S. The company estimates its total market opportunity for HFrEF in the U.S. to be $10.5 billion based on a prevalence model, and an annual market opportunity of $2.4 billion in the U.S. using an incidence-based model. Approximately 64 million people worldwide suffer from HF, including about 6.7 million in the U.S.